AR048279A1 - La forma ii cristalina de cabergolina - Google Patents

La forma ii cristalina de cabergolina

Info

Publication number
AR048279A1
AR048279A1 ARP010101262A ARP010101262A AR048279A1 AR 048279 A1 AR048279 A1 AR 048279A1 AR P010101262 A ARP010101262 A AR P010101262A AR P010101262 A ARP010101262 A AR P010101262A AR 048279 A1 AR048279 A1 AR 048279A1
Authority
AR
Argentina
Prior art keywords
cabergoline
cabergolina
crystal
solvent
crystallization
Prior art date
Application number
ARP010101262A
Other languages
English (en)
Inventor
Attilio Tomasi
Stefania Megenes
Giuliano Ramella
Mario Ungari
Marco Pandolfi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of AR048279A1 publication Critical patent/AR048279A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se divulga la Forma II de cabergolina cristalina, una composicion farmacéutica que la contiene y un procedimiento para su preparacion. El procedimiento puede comprender la cristalizacion de una solucion de cabergolina curda en un solvente orgánico a bajas temperaturas o bien someter a un procedimiento de lechada una mezcla de cabergolina Formas I y II en un solvente a una temperatura inferior a 30 degree C aproximadamente.
ARP010101262A 2000-03-24 2001-03-19 La forma ii cristalina de cabergolina AR048279A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0007307.2A GB0007307D0 (en) 2000-03-24 2000-03-24 Crystalline form || of cabergoline

Publications (1)

Publication Number Publication Date
AR048279A1 true AR048279A1 (es) 2006-04-19

Family

ID=9888432

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101262A AR048279A1 (es) 2000-03-24 2001-03-19 La forma ii cristalina de cabergolina

Country Status (31)

Country Link
US (2) US6673806B2 (es)
EP (1) EP1280803B1 (es)
JP (1) JP2003528874A (es)
KR (1) KR20020081492A (es)
CN (1) CN1221550C (es)
AR (1) AR048279A1 (es)
AT (1) ATE282038T1 (es)
AU (1) AU783064B2 (es)
BR (1) BR0109508A (es)
CA (1) CA2399540A1 (es)
CZ (1) CZ20023177A3 (es)
DE (1) DE60107074T2 (es)
DK (1) DK1280803T3 (es)
EA (1) EA004376B1 (es)
EE (1) EE200200544A (es)
ES (1) ES2231461T3 (es)
GB (1) GB0007307D0 (es)
HK (1) HK1052692B (es)
HU (1) HUP0300389A3 (es)
IL (1) IL151670A0 (es)
MX (1) MXPA02009284A (es)
MY (1) MY126071A (es)
NO (1) NO20024527D0 (es)
NZ (1) NZ521314A (es)
PE (1) PE20011087A1 (es)
PL (1) PL358252A1 (es)
PT (1) PT1280803E (es)
SI (1) SI1280803T1 (es)
SK (1) SK13572002A3 (es)
WO (1) WO2001072747A1 (es)
ZA (1) ZA200207151B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
BR0308304A (pt) * 2002-03-15 2004-12-28 Pharmacia Corp Processo para preparar forma i cristalina de cabergolina
IL155545A (en) * 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
CA2525104A1 (en) 2003-05-08 2004-11-25 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
US20130163062A1 (en) 2011-12-22 2013-06-27 Qualcomm Mems Technologies, Inc. Mechanical smart window with continuously tunable transmission

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US187013A (en) * 1877-02-06 Improvement in ovens for gas-stoves
US144516A (en) * 1873-11-11 Improvement in faucets
US149067A (en) * 1874-03-31 Improvement in steam-engine valve-gears
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB0007308D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007376D0 (en) 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
HK1052692A1 (en) 2003-09-26
EP1280803A1 (en) 2003-02-05
GB0007307D0 (en) 2000-05-17
CN1221550C (zh) 2005-10-05
ES2231461T3 (es) 2005-05-16
US20040072855A1 (en) 2004-04-15
US20030187013A1 (en) 2003-10-02
DK1280803T3 (da) 2005-01-24
HUP0300389A3 (en) 2004-08-30
ZA200207151B (en) 2003-09-05
IL151670A0 (en) 2003-04-10
SI1280803T1 (en) 2005-04-30
DE60107074T2 (de) 2005-10-20
EA004376B1 (ru) 2004-04-29
PE20011087A1 (es) 2001-10-04
EE200200544A (et) 2004-04-15
EA200201017A1 (ru) 2003-02-27
MY126071A (en) 2006-09-29
JP2003528874A (ja) 2003-09-30
MXPA02009284A (es) 2003-03-12
US6673806B2 (en) 2004-01-06
US6800635B2 (en) 2004-10-05
CN1418213A (zh) 2003-05-14
NO20024527L (no) 2002-09-20
BR0109508A (pt) 2002-12-17
AU783064B2 (en) 2005-09-22
NO20024527D0 (no) 2002-09-20
CZ20023177A3 (cs) 2003-03-12
SK13572002A3 (sk) 2003-04-01
PL358252A1 (en) 2004-08-09
KR20020081492A (ko) 2002-10-26
CA2399540A1 (en) 2001-10-04
NZ521314A (en) 2004-05-28
EP1280803B1 (en) 2004-11-10
DE60107074D1 (de) 2004-12-16
ATE282038T1 (de) 2004-11-15
AU4248201A (en) 2001-10-08
WO2001072747A1 (en) 2001-10-04
HK1052692B (zh) 2006-03-03
PT1280803E (pt) 2005-02-28
HUP0300389A2 (hu) 2003-07-28

Similar Documents

Publication Publication Date Title
AR048279A1 (es) La forma ii cristalina de cabergolina
PE20070492A1 (es) Forma cristalina delta del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
AR039666A2 (es) Procedimiento para la preparacion de la forma i de 6-o-metileritromicina a al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para prepararla forma i de 6-o-metileritromicina a y otros derivados
AR038648A1 (es) Hormona paratiroidea en forma cristalina y proceso para purificar la hormona paratiroidea y obtener dicha forma cristalina
GT199900203A (es) Composiciones de celecoxib.
PE20120663A1 (es) Anticuerpos anti-htnf alfa cristalinos
EA200702139A1 (ru) Масла капсаициноидов и способы их получения и применения
AR077416A2 (es) Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos
BR0114846A (pt) Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h
JP2004514737A5 (es)
DE602006014135D1 (de) Stent aus rekristallisiertem, texturiertem Iridium
PE20061014A1 (es) Clorhidrato de lercanidipina amorfo
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
HUP0500733A2 (hu) IGF-1 kristályosítása
WO2004077390A3 (fr) Melanges cristaux liquides nematiques pour dispositifs d'affichage bistables
AR017754A1 (es) Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento
BRPI0400375A (pt) Processo para remover vìrus em soluções de fibrinogênio para aplicação terapêutica e fibrinogênio obtido pelo dito processo
AR041678A1 (es) Formas cristalinas de clorhidrato de donepezil
MY125975A (en) Crystalline form vii of cabergoline
AR035553A1 (es) Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos.
TR200002647T1 (tr) Termal buharlaşma preparasyonu ve bu preparasyonu kullanarak kimyasal maddelerin termal buharlaştırılması için yöntem
AR019953A1 (es) Formas cristalinas i y ii de (r)-(+)-n-[[3-[1-benzoil-3-(3,4-diclorofenil)piperidin-3-il]prop-1-il]-4-fenilpiperidin-4-il]-n-metilacetamida (osanetant),composicion farmaeutica que las comprende y procedimiento para su preparacion de acuerdo a la mezcla de solvente y temperatura utilizado
BR0312604A (pt) ácidos imido-alcanpercarboxìlicos, composições, e, processo para a preparação e uso de ácidos imido-alcanpercarboxìlicos
BRPI0408752A (pt) processo para o preparo de um polimorfo de maleato de rosiglitazona
IS6224A (is) Aðferð til kristöllunar N- (1(S)-etoxýkarbonýl-3-fenýlprópýl)-L-alanín-N-karboxýlanhýdríðs

Legal Events

Date Code Title Description
FB Suspension of granting procedure